etodolac has been researched along with Prostatic Neoplasms in 6 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we show that the R-enantiomer of the nonsteroidal antiinflammatory drug etodolac inhibited tumor development and metastasis in the transgenic mouse adenocarcinoma of the prostate (TRAMP) model, by selective induction of apoptosis in the tumor cells." | 3.73 | The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. ( Bernasconi, M; Carson, DA; Corr, M; Cottam, HB; James, SY; Kolluri, SK; Leoni, LM; Liu, W; Lu, D; Zhang, XK, 2005) |
| "Compound 9 exhibited anticancer activity with an IC(50) value of 54 µM (22." | 1.39 | Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. ( Akbuğa, J; Bingöl-Özakpınar, Ö; Çevik, Ö; Çıkla, P; Küçükgüzel, ŞG; Özbaş-Turan, S; Özsavcı, D; Şahin, F; Şener, A, 2013) |
| "To assess the role of COX-2 in prostate cancer, we investigated whether the inhibition of COX-2 affected the proliferation of prostate cancer cells." | 1.31 | Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. ( Kamijo, T; Kitamura, T; Nagatomi, Y; Sato, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Çıkla, P | 1 |
| Özsavcı, D | 1 |
| Bingöl-Özakpınar, Ö | 1 |
| Şener, A | 1 |
| Çevik, Ö | 1 |
| Özbaş-Turan, S | 1 |
| Akbuğa, J | 1 |
| Şahin, F | 1 |
| Küçükgüzel, ŞG | 1 |
| Lowenthal, MN | 1 |
| Tombak, A | 1 |
| Lowenthal, A | 1 |
| Hedvat, M | 1 |
| Jain, A | 1 |
| Carson, DA | 2 |
| Leoni, LM | 2 |
| Huang, G | 1 |
| Holden, S | 1 |
| Lu, D | 2 |
| Corr, M | 2 |
| Fox, W | 1 |
| Agus, DB | 1 |
| Kolluri, SK | 1 |
| James, SY | 1 |
| Bernasconi, M | 1 |
| Liu, W | 1 |
| Cottam, HB | 1 |
| Zhang, XK | 1 |
| Shigemura, K | 1 |
| Shirakawa, T | 1 |
| Wada, Y | 1 |
| Kamidono, S | 1 |
| Fujisawa, M | 1 |
| Gotoh, A | 1 |
| Kamijo, T | 1 |
| Sato, T | 1 |
| Nagatomi, Y | 1 |
| Kitamura, T | 1 |
6 other studies available for etodolac and Prostatic Neoplasms
| Article | Year |
|---|---|
Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Dose-Response Rel | 2013 |
Secondary hypertrophic osteoarthropathy (HOA) mimicking primary HOA (pachydermoperiostitis or Touraine-Solente-Golé) syndrome.
Topics: Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase Inhibitors; Diagnosis, Differenti | 2004 |
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Blotting, Western; CD36 Antigens; Cell Line; Cell Lin | 2004 |
The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Eto | 2005 |
Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.
Topics: Animals; Cell Division; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Male; Mice; Mice, Nude; Prost | 2005 |
Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Fragmentation; Dose-Re | 2001 |